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An immunotoxin is a macromolecular drug which consists of
a monoclonal antibody linked to a protein toxin. The
antibody transports the toxin in the body and selectively
targets it to tumour cells by binding to a cell-surface antigen
expressed uniquely or at elevated levels on the tumour com-
pared with normal tissues. The toxin then enters the cell and
incapacitates it by irreversibly blocking an essential metabolic
process.
A unique combination of three properties distinguishes
immunotoxins from other forms of antibody-targeted therapy
(Embleton, 1987; Bagshawe, 1989; Epenetos & Kosmas,
1989; Wawrzynczak & Davies, 1990). First, the potent
cytocidal action of immunotoxins is independent of any
secondary agent or host accessory mechanisms. Second,
immunotoxins are not harmful to non-malignant cells unless
they bind inadvertantly and can be internalised efficiently.
Third, the mechanisms by which immunotoxins intoxicate
cells are quite distinct from those exploited by conventional
chemotherapeutic drugs or radiation treatments.
Experimental studies ofmonoclonal antibodies armed with
toxins have gathered momentum in recent years for two main
reasons: first, the failure of standard therapeutic strategies to
improve treatment in many different malignancies and
second, the generally disappointing results ofimmunotherapy
trials with unarmed monoclonal antibodies. Immunotoxins
against most of the common human cancers have been de-
scribed, many exert a potent and selective cytotoxic action
against tumour cells in culture and in animal models of
malignancy, and several are in clinical trials (reviewed in
Vitetta et al., 1987; Blakey et al., 1988b; Frankel, 1988;
Blattler et al., 1989; FitzGerald & Pastan, 1989).
Toxin structure and action
The protein toxins employed in immunotoxins are complex
and highly potent molecules whose ultimate action is the
inactivation ofprotein synthesis within target cells (Figure 1).
The bacterial toxins, diphtheria toxin (DTX) and Pseudomonas
exotoxin (PE), inactivate the eukaryotic elongation factor-2
(EF-2). The toxins derived from plants, ricin and abrin, are
enzymes that inactivate eukaryotic ribosomes. In every case,
intoxication requires that the enzymic portion of the toxin is
transferred to the cytosol from an initial binding site on the
cell surface and depends on the co-ordinated action of several
parts of the toxin molecule with distinct functions (Figure 2).
Diphtheria toxin is synthesised as a 58 kDa single-chain
protein. The toxin contains an arginine-rich polypeptide loop
region which is readily cleaved by cellular proteases to
generate a molecule containing a 21 kDa A chain and a
37 kDa B chain held together by a single disulphide bond.
The toxin binds to a specific human cell surface receptor,
probably an anion antiporter, via the B chain. The surface-
bound toxin is then internalised by receptor-mediated
Received 9 April 1991; and in revised form 20 May 1991.
DTx PE Ricin
Figure 1 Schematic representations of toxin molecular structure.
DTx, diphtheria toxin: A, catalytic fragment, B, binding fragment.
PE, Pseudomonas exotoxin: Ia,Ib - binding domain, II - trans-
location domain, III - catalytic domain. The shaded segments
mark the position of the protease-sensitive loop region. Ricin: A,
active chain, B, binding chain.
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Figure 2 Generalised scheme of the mechanism of cell intoxica-
tion by toxins and immunotoxins.
endocytosis via coated pits. At the low pH of the endosomal
compartment, the B chain undergoes a conformational
change to expose hydrophobic regions, inserts into the vesicle
membrane bilayer, and forms cation-selective channels. Con-
comitantly, the A chain is translocated across the membrane
to the cytosol. Finally, the A chain catalyses the ADP-
ribosylation and inactivation of EF-2 causing the complete
suppression of protein synthesis and bringing about cell
death.
The molecular architecture of PE differs from that of DTx
in detail but it too contains domains involved with cell
binding, translocation and ADP-ribosylation. PE appears to
follow a grossly similar mechanism of cell intoxication
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although it binds to a cell surface receptor distinct from that
recognised by DTx. The 66 kDa single-chain toxin contains a
disulphide-linked polypeptide loop reminiscent of the DTx
loop in domain II. Intracellular cleavage of the loop region
generates a 28 kDa fragment involved with cell binding and a
37 kDa catalytic fragment. The catalytic fragment is then
translocated to the cytosol with concomitant or subsequent
separation from the binding fragment by reduction (Ogata et
al., 1990). A second feature of PE important to toxicity is the
presence of an amino acid sequence at the C-terminus of the
catalytic fragment which resembles the consensus sequence
KDEL responsible for signalling the retention of soluble
proteins within the endoplasmic reticulum (Chaudhary et al.,
1990b). Binding of the catalytic fragment to the KDEL-
receptor may be an essential step leading to its translocation
to the cytosol.
Ricin in its native form consists of an A chain and a B
chain, each subunit a 32 kDa glycosylated polypeptide,
linked by a single disulphide bond. The A chain is a
ribosome-inactivating protein (RIP) which catalytically and
irreversibly inactivates the eukaryotic 60S ribosomal subunit
by a specific N-glycosidic cleavage of the 28S rRNA. The B
chain's primary role is to bind the toxin to the surface of
cells via ubiquitous galactose-containing glycolipids and
glycoproteins. The toxin is then routed to the trans-Golgi
network of the exocytic pathway from which compartment
the A chain may become translocated to the cytosol. A
second role proposed for the B chain independent of its
saccharide-binding ability is promotion of the process of A
chain translocation. The mechanism of this facilitation is
obscure. An intriguing possibility, by analogy with the ex-
ample of PE, is that a part of the B chain structure unrelated
to galactose-binding could signal the retention of the toxin in
the translocation-active compartment.
Immunotoxin design and activity
Immunotoxins comprising intact toxins are constructed with
the aid of chemical agents chosen to provide a stable cross-
link between the toxin and antibody. Those made with native
toxin molecules generally exhibit the high potency against
target cells that is characteristic of the toxins themselves.
However, such immunotoxins have the disadvantage that
they can also cross-react with cells lacking the target antigen
via the natural cell-binding sites of the toxin. The practical
use of immunotoxins for systemic therapy depends on means
to circumvent this problem of non-selectivity. The simplest
tactic, to eliminate the binding component of the toxin in its
entirety and to target the enzymically active portion only, has
so far been most successful with the plant toxins. In this case,
the isolated A chain is chemically cross-linked to antibody by
means of a disulphide bond which is essential for maximal
cytotoxic activity.
Ricin A chain is approximately 100,000-fold less toxic than
ricin toxin because it cannot bind strongly to most cells nor
gain efficient entry to the cytosol. For this reason,
immunotoxins containing ricin A chain have high selectivity
for target cells. In contrast to immunotoxins made with
native toxins, which exploit the natural pathway of toxin
entry, A chain immunotoxins rely on the target antigen to
mediate entry to the cell. The potency of A chain
immunotoxins thus depends upon the amount that binds to
the target cell surface and upon the efficiency with which the
antigen-determined pathway of internalisation delivers the A
chain to the translocation compartment. Depending upon the
nature of the target antigen, some A chain immunotoxins
exert cytotoxic effects matching or even surpassing those of
ricin whereas others are only slightly more potent than the
unconjugated A chain.
The cytotoxic activity of weakly active ricin A chain
immunotoxins can be enhanced by restoring the B chain to
assist the process by which the A chain is delivered to the
cytosol. Native B chain potentiates A chain immunotoxin
activity against target cells in culture but its use in vivo is
problematic because B chain with unhindered galactose-
binding sites mediates non-specific toxic effects. An alterna-
tive is to use a structurally modified B chain lacking
galactose-binding ability and direct it to the target cell by
means of antibody (Wawrzynczak et al., 1988). Neither of
these means of potentiating A chain immunotoxin activity
can apparently match the effectiveness of incorporating the
entire ricin molecule in a single immunotoxin construct
(Wawrzynczak et al., 1991d).
An alternative to the A chains of plant toxins for
immunotoxin construction are naturally occurring single-
chain ribosome-inactivating proteins which lack the counter-
part of the toxin B chain. 30kDa single-chain RIPs from
plants, such as gelonin and saporin, resemble the toxin A
chains in mechanism of action but have different structural,
physicochemical and biological properties. Another group of
single-chain RIPs is found in strains of the Aspergillus
mould. These 17 kDa RIPs, typified by oa-sarcin and restricto-
cin, differ from the plant enzymes both in structure and in
mode of action.
Clinical trials of ricin A chain immunotoxins
Clinical trials of systemic immunotoxin therapy were first
conducted in patients with B cell chronic lymphocytic
leukaemia. In patients treated with a ricin A chain immuno-
toxin directed against the CD5 antigen, saturation ofbinding
to leukaemic cells in the circulation was demonstrated. A
transient reduction in white blood cell count was followed by
the appearance of cells repopulating the bloodstream from
the marrow or lymph nodes. This response was similar to
that previously seen in patients treated with unconjugated
monoclonal antibody and could have been predicted given
the poor toxicity of the immunotoxin to target cells. No
sustained benefits were obtained and there were no toxic
side-effects (Hertler & Frankel, 1989).
The largest trial to date has been conducted in over 100
patients with metastatic melanoma treated with a ricin A
chain immunotoxin recognising a high molecular weight
antigen (Spitler et al., 1989). Disease stabilisation or mixed
responses were observed in about one third of patients fol-
lowing a single course ofimmunotoxin therapy and there was
one complete response. The presence of immunotoxin was
demonstrated in tissue samples of metastatic lesions derived
from a number of patients. Tumour regression tended to
occur in pulmonary, lymph node and soft tissue metastases
rather than in abdominal visceral lesions; progression occur-
red in the non-responding sites and by development of new
metastases (Oratz et al., 1990). Interestingly, the observed
regressions took place over a matter of months following
immunotoxin therapy.
Seventeen patients with metastatic colon cancer have been
treated with a single course of a ricin A chain immunotoxin
recognising a 72 kDa tumour-associated antigen in a phase I
dose-escalation study (Byers et al., 1989). Mixed responses
were detected in five patients; three had a decrease in the size
of large hepatic metastases and disappearance of smaller
lesions, others showed regression of pulmonary and supra-
clavicular node metastases. In this study also, tumour regres-
sions occurred over the course of several months following
treatment.
Two phase I studies of an immunotoxin consisting of
recombinant ricin A chain linked to an antibody against a
tumour-associated epithelial antigen have been conducted in
breast cancer patients (Gould et al., 1989; Weiner et al.,
1989). Of nine patients treated, one showed a regression in a
lung nodule followed by the appearance of tumour at a
different site. Analysis of chest wall biopsies from a number
of patients failed to detect the presence of immunotoxin
despite evidence of target antigen expression on the tumour
cells.
The occurrence of tumour regression in some tumour sites
and not in others within the same patient could be ascribed
to differences in target antigen expression of lesions at626 E.J. WAWRZYNCZAK
different sites. Failure to detect immunotoxin in some lesions
suggests that differential penetration of metastases at
different sites by immunotoxin is also a likely explanation for
some of the observed differences in response. The fact that
tumour regressions persisted for a period of months follow-
ing the cessation of immunotoxin therapy suggests the
involvement of host responses because the anti-tumour action
of immunotoxins is comparatively rapid involving hours or
days at most. It is possible that immune effector mechanisms
were directly activated by the antibody component of the
immunotoxin following binding to the tumour cells. Alterna-
tively, the release of factors from disintegrating tumour cells
killed by the primary action of the immunotoxin may have
triggered further anti-tumour effects.
Toxic symptoms were similar in the three trials of
immunotoxin therapy in metastatic cancer. The dose-limiting
toxicity was a capillary leak syndrome, characterised by a fall
in the level of serum albumin and total serum protein in the
absence of proteinuria, accompanied by fluid shifts, weight
gain and peripheral oedema. In one study, increased levels of
factor VIII-related antigen were detected during the develop-
ment of the syndrome (von Wussow et al., 1988). Many
patients developed flu-like symptoms with malaise, loss of
appetite, mild fevers, chills, myalgia and arthralgia. Some
changes were noted in liver function and some mild neural
abnormalities such as a fall in voltage on electrocardiogram.
These toxic effects were transient and ceased shortly after
immunotoxin administration was discontinued. The most
severe toxicity was reported in a group of metastatic breast
cancer patients who received immunotoxin by continuous
infusion rather than as a bolus. The severe late sensorimotor
neuropathy that developed in this group was attributed to an
effect of the immunotoxin on Schwann cells leading to
demyelination, a cross-reactivity which had not been
predicted by pre-clinical studies.
A common feature of all the clinical trials in metastatic
cancer was the development of a humoral immune response
against the immunotoxin. The majority of patients analysed
were found to have generated an IgM and an IgG response
to both the toxin and murine antibody components (Durrant
et al., 1989; Mischak et al., 1990). In patients re-infused with
the anti-melanoma immunotoxin following the immune re-
sponse- to initial treatment, the half-life of the immunotoxin
was diminished according to the serum titre of reactive IgG
but no adverse effects were seen (LoBuglio et al., 1988). In
the patients receiving the anti-colon carcinoma immunotoxin,
the predominant response to the antibody was directed
against the idiotypic determinants; a component of this re-
sponse was able to block cell binding by the antibody and,
by implication, could inhibit immunotoxin binding (Durrant
et al., 1989).
Further clinical studies of ricin A chain immunotoxins are
in progress or are planned using immunotoxins made with
monoclonal antibodies recognising the CD5 antigen in
cutaneous T cell lymphoma, the CD7 antigen in T-cell acute
lymphocytic leukaemia, the CDl9 and CD22 antigens in
B-cell tumours, the CD30 antigen in Hodgkin's disease, and
the transferrin receptor in patients with tumours restricted to
the peritoneal cavity (Ghetie et al., 1988; Hertler et al.,
1989b; Engert et al., 1990; Bookman et al., 1990a).
Factors influencing A chain iimunotoxin efficacy
The therapeutic efficacy of A chain immunotoxins is cur-
rently limited by the relatively weak action of some
immunotoxins in vivo, by dose-limiting toxic side-effects, and
by the humoral immune response which invalidates repeated
administration.
Anti-tumour action
The selective cytotoxic activity of A chain immunotoxins
directed against a particular target antigen can be maximised
in two ways. Firstly, by enhancing potency with agents that
disrupt the normal pathways of antigen internalisation and
delay cellular breakdown of immunotoxin. Potentiating
agents shown to be effective in a number of systems in vitro
include lysosomotropic amines such as chloroquine and car-
boxylic ionophores such as monensin. In practice, a poten-
tiating dose is not readily achieved with these agents in vivo
because they are rapidly eliminated from the bloodstream.
Although monensin chemically linked to a carrier such as
human serum albumin potentiates immunotoxin activity and
has a longer blood half-life, its worth in vivo remains to be
established (Hertler et al., 1989a; Colombatti et al., 1990). A
second approach has been to screen for those monoclonal
antibodies recognising the target antigen which mediate the
most potent effects (Till et al., 1988). Monoclonal antibodies
recognising epitopes situated proximal to the cell membrane
can form A chain immunotoxins with substantially higher
target cell potency than antibodies having similar
immunochemical properties which are directed against more
distal epitopes possibly because the A chain is brought into
more intimate contact with cellular membranes (Press et al.,
1988; May et al., 1990).
A second restraint on anti-tumour efficacy is immunotoxin
stability. The survival of A chain immunotoxins in vivo is
influenced by the properties of the A chain and the manner
of its attachment to the antibody. Immunotoxins made with
native glycosylated A chains are rapidly eliminated from the
bloodstream via receptor-mediated recognition by cells of the
reticuloendothelial system, predominantly the Kupffer cells of
the liver. This carbohydrate-mediated clearance can be
avoided by the use of ricin A chain which has been chemi-
cally treated to abolish receptor binding, of recombinant ricin
A chain from Escherichia coli, or of the aglycosyl abrin A
chain (Thorpe et al., 1988; Wawrzynczak et al., 1990, 1991a).
A chain immunotoxins break down in vivo to release the
antibody and A chain constituents because the disulphide
linkage, necesssarily included in their construction to maxi-
mise activity, is susceptible to reduction by endogenous
glutathione. The rate of splitting can be minimised by the use
of hindered cross-linking agents, or of abrin A chain, both
forming conjugates which are more resistant to breakdown
than the conventional type of A chain immunotoxin (Thorpe
et al., 1988; Wawrzynczak et al., 1990). A further complica-
tion is that disulphide-linked A chain immunotoxins can
interact selectively with M2-macroglobulin in vivo by thiol-
disulphide interchange to form high molecular weight com-
plexes (Ghetie et al., 1991) A novel idea is to attach the A
chain stably by means of the DTx polypeptide loop which
can be proteolytically cleaved within the target cell to yield
an active disulphide-linked A chain derivative (O'Hare et al.,
1990). This tactic could circumvent the premature inactiva-
tion of immunotoxin by splitting or complexation.
A third factor influencing the anti-tumour action of
immunotoxins is the efficiency with which they localise in
tumours. The rate of extravasation of macromolecules is
determined in part by molecular size (Figure 3). Tumour
localisation is significantly enhanced for ricin A chain
immunotoxins made with antibody Fab' or F(ab')2 fragments
compared with analogous immunotoxins made with intact
antibody (Fulton et al., 1988a; Rostaing-Capaillon & Casel-
las, 1990). The molecular size of immunotoxins can also be
reduced by selecting smaller toxin components such as a-
sarcin or restrictocin which form immunotoxins having com-
parable potency to those made with the larger plant-derived
toxin A chains or RIPs (Orlandi et al., 1988; Conde et al.,
1989; Wawrzynczak et al., 1991c).
Toxicity
Toxis side-effects can result from the unwanted interaction of
the A chain component of the immunotoxin with some nor-
mal tissues. The toxic effects of immunotoxins made with
native glycosylated ricin A chain against hepatic
non-parenchymal cells are abrogated by eliminating the
carbohydrate side-chains of the A chain involved in receptor-
mediated recognition. Undesirable interactions can also occurSYSTEMIC IMMUNOTOXIN THERAPY OF CANCER 627
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Figure 3 Relative molecular sizes of antibody and toxin com-
ponents for the assembly of therapeutic immunotoxins.
independently of carbohydrate recognition as in the case of
immunotoxins made with the aglycosyl RIP saporin which
bind to and are toxic for hepatic parenchymal cells (Blakey et
al., 1988a). Immunotoxins can be toxic to non-malignant
cells as well as to tumour cells because of cross-reactivity
mediated by the antibody component. Non-malignant cells
which express a low level of the target antigen are likely in
general to be less susceptible to killing than tumour cells.
Moreover, normal tissues may be able to tolerate con-
siderable damage provided that the cells inadvertantly killed
by immunotoxin treatment can be regenerated from target
antigen-negative progenitor cells. However, the consequences
of cross-reactivity may be severe as in the case of the
neurotoxicity observed in one of the breast carcinoma clinical
trials (Gould et al., 1989).
The general dose-limiting toxicity associated with ricin A
chain immunotoxins is a capillary leak syndrome also seen in
animal studies and similar to that observed following admini-
stration of interleukin-2 or interferon-y. The occurrence of
the syndrome is common to immunotoxins made with different
monoclonal antibodies and with native or aglycosyl ricin A
chains but the underlying mechanism is uncertain. One pos-
sibility is that immunotoxins have indirect effects on
endothelial cells by binding to monocytes via a common
structure, such as the Fc domain of the antibody component,
and triggering the release of cytokines (Weiner et al., 1989).
A second explanation for damage to the vascular endo-
thelium is that the constitutive, non-selective uptake of
immunotoxin from the bloodstream by endothelial cells
occurs at a level leading to direct toxic effects on the cells.
Immunogenicity
The development of a humoral immune response can com-
promise immunotoxin action by increasing the rate of blood
clearance, by directly blocking the combining site of the
antibody component, or by rendering the A chain ineffective.
The extent of the antibody response to immunotoxin in
animals can be significantly reduced by administration of
cyclophosphamide in immunosuppressive doses (Stoudemire
et al., 1990). In further clinical trials of the anti-melanoma
immunotoxin, attempts have been made to increase the dura-
tion of therapy by suppressing the host response with
cyclophosphamide, prednisone, azathioprine and cyclosporin
A, used singly or in combination (Spitler et al., 1989; Oratz
et al., 1990). Some immunosuppressive regimens were able to
control the response to a single infusion of immunotoxin but
not to repeated administration. Another approach is to selec-
tively suppress the action of T helper cells in the immune
response. In preliminary studies using a murine model, the
administration of monoclonal CD4 antibody completely
abrogated the antitoxin response to an immunotoxin (Jin et
al., 1991).
Therapy with intact toxins
The therapeutic use of intact protein toxins has been
inhibited by the high toxicity associated in major part with
non-specific binding via the natural cell-binding sites of the
native toxins. A trial of intraperitoneal therapy with an
anti-ovarian carcinoma immunotoxin made with native PE
was discontinued due to severe and unexplained neurotoxi-
city (Bookman et al., 1990b). The elimination of the N-
terminal binding domain (Ia) of PE results in a truncated
toxin molecule called PE40. The cytotoxicity of this fragment
is decreased by more than 100-fold although PE40
immunotoxins are about 10-fold less potent than their intact
PE analogues. Mutagenesis studies have identified four
positively-charged amino acid residues of the PE binding
domain which contribute to its toxicity in animals; their
replacement with negatively-charged glutamic acid residues
generates an analogue known as PE664lu which has 150-fold
lower toxicity and should therefore be more suitable for
therapy (Chaudhary et al., 1990c).
Removal of a C-terminal 17 kDa portion of DTx compris-
ing the cell-binding domain of the B chain eliminates the
non-specific toxicity of a DTx immunotoxin but decreases its
target cell toxicity by 100-fold, probably because the remnant
B chain is conformationally destabilised. A more useful can-
didate is a full-size DTx with two amino acid residue
replacements in the binding domain. The mutant DTx, called
CRM107, has 10,000-fold lower toxicity than native DTx but
forms immunotoxins with target cell toxicity equipotent with
their native DTx counterparts (Johnson et al., 1988). An
anti-transferrin receptor immunotoxin made with the DTx
CRM107 mutant has been developed for the treatment of
leptomeningeal neoplasms, such as glioblastoma and
medulloblastoma which over-express the transferrin receptor,
by the intrathecal route of administration (Johnson et al.,
1989).
The galactose-binding sites of ricin become partially oc-
cluded following attachment to antibody but the blockade is
insufficiently complete to be of value. A blocked ricin having
a non-target cell toxicity about 1,000-fold lower than that of
the native toxin has been generated by chemically attaching
oligosaccharide ligands with a high affinity for the galactose-
binding sites (Lambert et al., 1991). Trials of immunotoxins
made with this blocked ricin are in progress or planned to
take place in patients with B-cell tumours and small cell lung
carcinoma. Genetic engineering of ricin to eliminate the
galactose-binding sites has not been possible because the
toxin's extreme potency precludes its useful production in
eukaryotic expression systems. Instead, ricin A and B chains
have been separately cloned and expressed from bacteria in
biologically active form. A recombinant B chain with
diminished saccharide-binding ability has been generated by
substitution of a single binding site amino acid residue
(Vitetta & Yen, 1990).
Prospects
The principal aim of all cancer therapies is to maximise
inhibition of tumour growth and to minimise toxic side-
effects. In common with conventional anti-cancer drugs, im-
provements in the therapeutic performance of immunotoxins
will stem from the development of analogues with improved
properties and from a better understanding of the obstacles
to their successful action.
Immunotoxins made with native toxins generally have a
higher cytotoxic potency than A chain immunotoxins, intoxi-
cate cells more rapidly, and achieve a higher clonogenic cell
kill. In the case of intact toxins lacking functional binding
sites, which rely on the target antigen for internalisation and
intact antibody
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0
intact toxin
(60 kDa)628 E.J. WAWRZYNCZAK
cannot exploit the natural route of entry, the advantages are
less well documented. Moreover, targeted toxin analogues
which are able to kill cells efficiently whatever the pathway of
uptake are likely to prove more toxic to cells lacking the
target antigen than A chain immunotoxins whose potency is
a function of the antigen-mediated pathway of uptake.
At present, the best candidates for systemic therapy are
potent A chain immunotoxins which can possess a high
selectivity of action, greater than 100,000-fold, exceeding that
which can be achieved with intact toxins manipulated to
minimise binding to natural toxin receptors. Nevertheless, it
remains the case that for the majority of target antigens only
immunotoxins made with intact toxins have demonstrated
sufficient potency to be of therapeutic value. A more detailed
understanding of the intracellular fate of A chain immuno-
toxins and the structural features determining routing and
translocation may allow further modifications designed to
enhance their intrinsic potency.
The extent of immunotoxin localisation in tumour and
hence the likely anti-tumour effect is determined by the blood
concentration over time, the rate of extravasation and the
degree of penetration. Native DTx administered intra-
venously is capable of eradicating large solid human tumour
masses located in the peritoneal cavity or in the brain paren-
chyma of experimental animals which are not susceptible to
the action of the toxin (Raso & McGrath, 1989; Wrobel et
al., 1990). In contrast, a DTx immunotoxin made with intact
antibody extravasates less rapidly than the toxin due to its
considerably larger size but can accumulate in the tumour to
a higher level because of a comparatively slower rate of
blood clearance and higher cell binding (Sung et al., 1990). A
disadvantage of the native toxins, and of their more selective
analogues, is that their size cannot be further reduced with-
out substantially diminishing their activity. By comparison,
the plant and fungal RIPs are about one half and one
quarter the size of the intact toxins respectively, differences
that become increasingly significant the further the size of the
antibody component is decreased (Figure 3).
In principle, the size of the antibody component can be
reduced by using smaller recognition units than the
proteolytically-derived Fab fragments, for example, an Fv
domain comprising the heavy and light chain variable
domains of a single Fab arm. Indeed, recombinant
immunotoxins have been created that consist of a single-
chain Fv domain from an antibody recognising the human
interleukin-2 receptor in peptidyl linkage to either PE40 or a
truncated DTx analogue (Chaudhary et al., 1989; 1990a).
However, the potential advantage of enhanced access to
tumour by miniaturised immunotoxins is balanced by two
possible disadvantages. First, immunotoxins made with
univalent antibody fragments are usually less potent than
their bivalent counterparts because they bind to the target
cell surface less avidly. Second, the biological half-life of
immunotoxins made with antigen-binding fragments of
antibody is diminished by the absence of the Fc portion
responsible for the regulation of IgG catabolism. The
judicious recombination ofantibody domains and toxins with
the appropriate properties can be expected to evolve
immunotoxin molecules of novel design with improved
tumour localisation properties.
Toxic side-effects mediated via antigen binding can be
minimised by selecting second generation monoclonal
antibodies with the highest selectivity for the target tumour
and by removing the possibility of non-specific interaction,
for example, by selectively modifying regions of the antibody
that mediate binding to cellular Fc receptors but are not
involved with the control of antibody half-life (Wawrzynczak
et al., 1991b). Further modifications of toxin structure and
immunotoxin design by recombinant methods are also likely
to minimise cross-reaction with normal tissues. The relation-
ship between immunotoxin pharmacokinetics and toxicity is
less well understood. The exposure of normal tissues, and
consequently their susceptibility to damage, is increased by
prolonging the blood half-life of immunotoxins. However, in
therapy experiments, immunotoxins with longer in vivo sur-
vival also display superior anti-tumour effects and have an
improved therapeutic index compared with shorter-lived
analogues (Fulton et al., 1988b; Thorpe et al., 1988).
The humoral response in Man to mouse antibody can be
mitigated by replacing the mouse constant domains and
framework regions of the variable domains with the
analogous structures derived from human antibody. This
strategy does not obviate the anti-idiotypic response, nor, in
the case of immunotoxins, the equal problem of the response
to the toxin component. An additional problem with the use
of the bacterial toxins in Man is that significant numbers of
patients, especially those immunised with the BCG vaccine,
have a pre-existing immune response to the toxins. Some
transient benefit may be expected by engineering out the
immunodominant epitopes of the toxin molecules. The best
long-term solution to the obstacle of immunogenicity,
relevant to immunotoxins and other natural or recombinant
therapeutic proteins, is likely to be a strategy able to actively
suppress responses to soluble and cell-binding immunogens.
The target antigens which have generally been selected for
immunotoxin therapy are expressed by the majority of malig-
nant cells in a tumour. However, the phenomenon of tumour
cell heterogeneity is a fundamental limitation to the
immunotoxin approach. Malignant cells expressing the target
antigen at low levels tend to be less susceptible to
immunotoxin and a proportion of tumour cells can be resis-
tant to killing because they fail to internalise surface-bound
immunotoxin. This may not be an obstacle to inducing
tumour regression provided that immunotoxin treatment
inflicts sufficient damage to activate natural host defences. A
practical solution is to use immunotoxins in combination
with agents that bring about tumour cell killing by different
mechanisms. Anti-tumour effects superior to the use of either
the immunotoxin or of another agent alone can be achieved
in three ways. Firstly, by synthesising radioimmunotoxins
that simultaneously target a toxin and a radionuclide (Man-
ske et al., 1988; Ito et al., 1991). Secondly, by administering
immunotoxins in parallel with or following cytoreductive
agents such as cyclophosphamide or daunorubicin (Pearson
et al., 1989a; Yokota et al., 1990). Thirdly, by using recom-
binant human interferon-x either to enhance target cell
sensitivity to immunotoxin directly, or to stimulate host-
mediated effector mechanisms (Pearson et al., 1990; Yokota
et al., 1990).
Conclusion
Immunotoxins can be administered to Man systemically
within acceptable limits to toxicity and can elicit anti-tumour
effects in cancer patients with disseminated disease who have
failed conventional treatment. Future improvements in
clinical performance can be expected from developments in
three areas. First, the generation of novel immunotoxins with
defined structure having improved potency and selectivity,
greater stability, enhanced tumour localisation, lower toxicity
and reduced immunogenicity. Second, elucidation of the
basic mechanisms responsible for immunotoxin-induced toxi-
city and immune responses and the invention of novel
strategies to minimise the limitations these side-effects place
upon therapy. Third, the use of immunotoxins in clinical
settings where there is a potential therapeutic advantage of
either combination therapy with agents having complemen-
tary anti-tumour activities, or second-line therapy when the
onset of resistance to conventional treatment first thwarts
further clinical benefit.
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